Horizon Pharma has formed an executive committee and has restructured its U.S. commercial operations into three divisions, each led by a general manager reporting to Timothy P. Walbert, chairman, president and chief executive officer. Additionally, Todd N. Smith, executive vice president, chief commercial officer has resigned from the company.

In addition to Mr. Walbert, the executive committee includes: Robert F. Carey, executive vice president, chief business officer, Paul W. Hoelscher, executive vice president, chief financial officer, Barry J. Moze, executive vice president, corporate development, and Jeffrey W. Sherman, M.D., FACP, executive vice president, R&D and chief medical officer.

The U.S. Commercial Organization will be led byTerry Evans, senior vice president and general manager, primary care, managed care and trade, Brian Andersen, vice president and general manager, orphan, and Vikram Karnani, vice president and general manager, specialty.

“The closing of the Vidara Therapeutics International plc acquisition provided us with the opportunity to create an organizational structure with the flexibility to accommodate a growing portfolio of products,” said Timothy P. Walbert, chairman, president and chief executive officer. “As we continue to drive product sales and aggressively pursue potential acquisitions, we are developing a strong operating and financial platform for future growth.  In addition, on behalf of the company, I would like to thank Todd for his commercial and business development leadership and contribution to our progress over the last four years and we wish him success as he continues his career.”